Anticancer Peptides advanced
Ixazomib Oral Proteasome Inhibitor
First oral boronic acid proteasome inhibitor for multiple myeloma, enabling convenient oral chemotherapy regimens.
By Encyclopeptide Editorial | 1 min read
ixazomib proteasome oral multiple-myeloma cancer
Chemical Identity
| Property | Value |
|---|---|
| Chemical Formula | C14H19BCl2N2O4 |
| Molecular Weight | 361.03 g/mol |
| CAS Number | 1072833-17-2 |
| Product Name | Ninlaro |
| Route | Oral |
Structure
Ixazomib is a prodrug that hydrolyzes in plasma to its active form, a boronic acid that reversibly inhibits the 20S proteasome. It is the first oral proteasome inhibitor approved.
Clinical Applications
- Multiple myeloma (relapsed/refractory)
- Used with lenalidomide and dexamethasone (IRd regimen)
- TOURMALINE-MM1 trial demonstrated PFS benefit
Biological Significance
This molecule plays important roles in biological systems and has potential therapeutic applications.
References
- Encyclopeptide Database. “Ixazomib Oral Proteasome Inhibitor” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Ixazomib Oral Proteasome Inhibitor with interactive quizzes on Wikipept.
Take a Quiz on Wikipept